Suggested remit: To appraise the clinical and cost effectiveness of entrectinib within its marketing authorisation for treating ROS1 fusion-positive locally advanced or metastatic non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 1541

Project Team

Project lead Gavin Kenny

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Roche (entrectinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Society
  Cancer Research UK
  National Lung Cancer Forum for Nurses (NLCFN)
  Royal College of Physicians
  Royal College of Radiologists


Comparator companies None
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
15 June 2020 - 29 June 2020 Final appraisal document
23 December 2019 This appraisal was discussed by the technology appraisal committee on 20 November 2019. The committee’s decision will be released to consultees and commentators once positive CHMP opinion has been granted.
21 March 2019 Invitation to participate
30 January 2019 - 27 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 October 2018 In progress. Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance